Open Access Articles- Top Results for LY-293284


Systematic (IUPAC) name
Clinical data
141318-62-9 7pxY
PubChem CID 132345
ChemSpider 116875
Chemical data
Formula C19H26N2O
298.423 g/mol
 14pxY (what is this?)  (verify)

LY-293284 is a research chemical developed by the pharmaceutical company Eli Lilly and used for scientific studies. It acts as a potent and selective 5-HT1A receptor full agonist. It was derived through structural simplification of the ergoline based psychedelic LSD,[1] but is far more selective for 5-HT1A with over 1000x selectivity over other serotonin receptor subtypes and other targets.[2] It has anxiogenic effects in animal studies.[3]

See also


  1. ^ Monte AP, Marona-Lewicka D, Lewis MM, Mailman RB, Wainscott DB, Nelson DL, Nichols DE (June 1998). "Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity". Journal of Medicinal Chemistry 41 (12): 2134–45. PMID 9622555. doi:10.1021/jm980076u. 
  2. ^ Foreman MM, Fuller RW, Rasmussen K, Nelson DL, Calligaro DO, Zhang L, Barrett JE, Booher RN, Paget CJ, Flaugh ME (September 1994). "Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity". The Journal of Pharmacology and Experimental Therapeutics 270 (3): 1270–81. PMID 7523657. 
  3. ^ Cao BJ, Rodgers RJ (October 1998). "Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice". Psychopharmacology 139 (3): 185–94. PMID 9784072. doi:10.1007/s002130050703. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.